|1.||Fenaux, Pierre: 30 articles (10/2015 - 12/2005)|
|2.||Garcia-Manero, Guillermo: 23 articles (12/2015 - 07/2007)|
|3.||Gore, Steven D: 23 articles (03/2015 - 03/2009)|
|4.||Santini, Valeria: 23 articles (03/2015 - 03/2009)|
|5.||List, Alan F: 14 articles (09/2015 - 02/2010)|
|6.||Kantarjian, Hagop: 13 articles (08/2015 - 05/2005)|
|7.||Hellström-Lindberg, Eva: 12 articles (10/2015 - 01/2006)|
|8.||Beach, C L: 12 articles (07/2015 - 05/2005)|
|9.||Seymour, John F: 12 articles (07/2015 - 03/2009)|
|10.||Silverman, Lewis R: 12 articles (07/2013 - 05/2002)|
|1.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
11/01/2010 - "The earliest and the most successful epigenetic drug to date, 5-Azacytidine, is currently recommended as the first-line treatment of high-risk myelodysplastic syndromes (MDS). "
07/01/2013 - "These results demonstrate azacitidine benefit on overall survival compared with conventional care regimens in patients with higher-risk myelodysplastic syndromes who achieve hematologic response but never attain complete or partial remission, in addition to the survival advantage conferred by achievement of complete or partial remission."
01/01/2013 - "Around 6 weeks after this single azacitidine cycle, complete remission-according to international working group criteria-was observed with continuous improvement in peripheral blood counts to normal values, transfusion-independence, normal blast count (< 5 %) with normal morphology and flow cytometry, as well as a normal bone marrow karyotype and no dysplastic stigmata suggestive of a coexisting myelodysplastic syndrome. "
11/01/2010 - "Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. "
10/15/2006 - "Azacitidine administered in the outpatient setting is well tolerated and can induce complete hematological remission in patients with myelodysplastic syndromes (MDS). "
|2.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/01/2015 - "When compared with best supportive care, azacitidine significantly improved overall survival (hazard ratio [HR], 0.69; 95% CI, 0.54-0.87) and time to acute myeloid leukemia transformation (HR, 0.51; 95% CI, 0.35-0.74). "
11/01/2015 - "First, an acute myeloid leukemia patient showed life-threatening toxicities, but outstanding complete remission, after a single round of azacitidine. "
01/01/2013 - "Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia."
06/01/1982 - "Even when abnormal chromosomes are present, 5-azacytidine can induce complete remission in patients with previously treated ANLL."
01/01/2014 - "We present the first Jehovah's Witness patient with acute myeloid leukemia (AML) treated successfully with azacitidine. "
02/12/2015 - "Recently, azacytidine, a hypomethylating agent, was reported to induce hematologic/molecular remissions in some children with JMML, and its role in both reducing leukemia burden before HSCT and in nontransplant settings requires further studies. "
04/01/1981 - "Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group Study."
01/01/1981 - "During initial trials of 5-azacytidine in adults with advanced acute leukemia, we unexpectedly observed acid-base, fluid, and electrolyte abnormalities that contributed directly to the deaths of two early patients. "
04/01/2014 - "Mechanisms of resistance to azacitidine in human leukemia cell lines."
09/01/2013 - "Our data establish hENT1 as a key transporter for the cellular uptake of 5-azacytidine in leukemia cells and raise the possibility that hENT1 expression might be a useful biomarker to predict the efficiency of 5-azacytidine treatments. "
10/01/2013 - "Long term administration of 5-azacytidine resulted in reduction of DNA methylation of promoter loci, induction of glial differentiation, reduction of cell proliferation and a significant reduction in tumor growth. "
01/01/2015 - "Furthermore, this study identified a novel function of 5-azacytidine in promoting a TET-mediated generation of 5hmC suggesting that the availability of 5-AZA in cancer cells will have various effects on different epigenetic targets. "
11/15/2013 - "Our study also warrants further exploration in the potential therapeutic use of existing epigenetic targeting drugs (e.g., 5-azacytidine, SAHA) to reconstitute CACNA2D3-associated tumor suppression in NPC. "
10/01/2012 - "Numerous drugs that specifically target DNMTs are being tested in ongoing clinical trials for a variety of cancers, and data from finished trials demonstrate that some, such as 5-azacytidine, may even be superior to standard care. "
04/01/2007 - "Considering that 5-azacytidine potentiates hepatocarcinogenesis, more studies are needed to elucidate the efficacy and safety of this drug for cancer control."
|5.||Lung Neoplasms (Lung Cancer)
11/01/2010 - "The purpose of this study is to explore the therapeutic potential of regional administration (via the airways) of the demethylating agent 5-azacytidine (5-Aza) for the treatment of early lung cancer. "
10/01/2013 - "Collectively, these findings show that aerosolised 5-azacytidine targets the lung, effectively reprogrammes the epigenome of tumours, and is a promising approach to combine with other drugs for treating lung cancer."
10/01/2013 - "Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model."
11/01/2010 - "5-Azacytidine can reverse the hypermethylation in the human lung cancer cell lines at a nontoxic dose. "
11/01/2010 - "Intratracheally administered 5-azacytidine is effective against orthotopic human lung cancer xenograft models and devoid of important systemic toxicity."
|1.||DNA (Deoxyribonucleic Acid)
|4.||lenalidomide (CC 5013)
|5.||gemtuzumab (gemtuzumab ozogamicin)
|6.||Histone Deacetylase Inhibitors
|7.||A-Form DNA (A-DNA)
|9.||Etoposide (VP 16)
|10.||N- (2- aminophenyl)- 4- (N- (pyridin- 3- ylmethoxycarbonyl)aminomethyl)benzamide (MS 275)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Homologous Transplantation (Allograft)
|5.||Combination Drug Therapy (Combination Chemotherapy)